Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine given with hepatitis B vaccine: A randomized open-label trial

Bulletin of the World Health Organization

Volumn 86, Issue 6, 2008, Pages 443-451

  Capeding, Maria Rosario ^a   Cadorna Carlos, Josefina ^b   Book Montellano, May ^c   Ortiz, Esteban ^d  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b University of the East Ramon Magsaysay   (Philippines)

^c Mary Chiles Hospital   (Philippines)

^d SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B POLYRIBOSYLRIBITOL PHOSPHATE TETANUS TOXOID VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMAGGLUTININ ANTIBODY; HEPATITIS B VACCINE; PENTAXIM; RECOMBINANT HEPATITIS B VACCINE; RECOMVAX B;

ANTIBODY; IMMUNOASSAY; SAFETY; VACCINE;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIPHTHERIA; DROWSINESS; DRUG CONJUGATION; DRUG SAFETY; FEVER; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SEROLOGY; SIDE EFFECT; TETANUS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ANTIBODY FORMATION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; PHILIPPINES; POLYSACCHARIDES; VACCINES, COMBINED;

HAEMOPHILUS INFLUENZAE SEROTYPE B; HUMAN POLIOVIRUS 1; POLIOVIRUS;

EID: 44949262957     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.07.042143     Document Type: Article

References (22)

1. Pines E, Barrand P, Fabre P, Salomon H, Blondeau C, Wood SC, et al. New acellular pertussis-containing paediatric combined vaccines. Vaccine 1999;17:1650-6. PMID:10194818 doi:10.1016/S0264-410X(98)00422-8
2. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66. PMID:7659476
3. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-57. PMID:7659475
4. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997;16 Suppl 4;S90-6. PMID:9109163 doi:10.1097/00006454-199704001-00004
5. Edwards KM, Decker M. Pertussis vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th edn. Philadelphia, PA: Saunders Co.; 2004. 21:471-528.
6. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12. PMID:9364690 doi:10.1016/S0264-410X(97)00100-X
7. Therre H, Baron S. Pertussis immunisation in Europe - the situation in late 1999. Euro Surveill 2000;5:6-10. PMID:12631876
8. Pertussis vaccines. Wkly Epidemiol Rec 2005;80:29-40. PMID:15715139
9. United Nations prequalified vaccines (WHO list of vaccines for purchase by UN agencies as of April 2008). Available from: http://www.who.int/ immunization_standards/vaccine_quality/pq_suppliers/en/index.html [accessed on 5 May 2008].
10. Lagos R, Kotloff KL, Hoffenbach A, San Martin O, Abrego P, Ureta AM, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr Infect Dis J 1998;17:294-304. PMID:9576383 doi:10.1097/00006454-199809001-00010
11. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granstrom M, Blondeau C, et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998;17:1026-33. PMID:9849987 doi:10.1097/00006454-199811000-00013
12. Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schödel F, et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000;19:1119-27. PMID:11144370 doi:10.1097/00006454- 200012000-00001
13. Carlsson RM, Claesson BA, Fagerlund UE, Knutsson N, Laudin C. Antibody persistence in five-year old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002;21:535-41. PMID:12182378 doi:10.1097/00006454-200206000-00011
14. Kanra G, Selier T, Yurdakök K, Yavuz T, Baskan S, Ulukol B, et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTacP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 1999;18:947-54. PMID:10580209 doi:10.1016/S0264-410X(99)00331-X
15. Gylca R, Gylca V, Benes O, Melnic A, Chicu V, Weisbecker C, et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 2000;19:825-33. PMID:11115705 doi:10.1016/S0264-410X(00)00231-0
16. Krishnan R, Jadhav M, John TJ. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983;61:689-92. PMID:6605215
17. Plotkin SA, Vidor E. Poliovirus vaccine - inactivated. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders, 2004. pp. 625-49.
18. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acellular pertussis vaccines. [Appendix 2 SP-MSD]. Swedish Institute for Infectious Disease Control; 2006. Available from: http://www.smittskyddsinstitutet.se/upload/PDF-filer/seven-year-report-app-2-SP- MSD.pdf [accessed on 5 May 2008].
19. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003;21:2015-21. PMID:12706691 doi:10.1016/S0264-410X(02)00777-6
20. Hepatitis B vaccines. Wkly Epidemiol Rec 2004;79:255-64. PMID:15344666
21. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HA. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329-39. PMID:16249217 doi:10.1093/ije/dyi206
22. Greenberg DP, Wong VK, Partridge S, Howe BJ, Ward JI. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. Pediatr Infect Dis J 2002;21:769-76. PMID:12192167 doi:10.1097/00006454-200208000-00014